Cannabis Law Report

AUGUST 12, 2021

11, 2021 (GLOBE NEWSWIRE) COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the second quarter 2021 and gave an update on recent progress across its business. LONDON, Aug. Business highlights.

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Cannabis Law Report

DECEMBER 20, 2021

First Patient Expected to be Enrolled by Q2 of 2022. Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, signed a clinical trial agreement with Altasciences Company, Inc., Media: Laura Radocaj. BERWYN, Pa.–(BUSINESS

Clinical Trials 40

Clinical Trials Chronic Pain Pharmaceutical Data 40

CannaMD

NOVEMBER 6, 2019

Today, both patient experience and modern scientific research support claims of medical marijuana’s effectiveness for pain management. Questions included any changes in personal levels of opioid use when marijuana was also used, and the reasons why patients were substituting marijuana for prescription pain medications.

Marijuana 107

Marijuana Patients Clinical Trials Data 107

Cannabis Law Report

SEPTEMBER 29, 2021

Pre-clinical and initial clinical studies show that ANANDA’s Liquid Structure technology (licensed from Lyotropic Delivery Systems (LDS) Ltd. ANANDA Scientific Media Relations | Christopher Moore | 813 326 4265 | media@anandascientific.com. GREENWOOD VILLAGE, Colo. &

Clinical Trials 40

Clinical Trials Medicine Treatment Research and Development 40

Puff Puff Post

SEPTEMBER 16, 2019

16, 2019 /CNW/ – Québec doctors have a new tool at their disposal for learning about medical cannabis and its viability as a treatment option for their patients. “It is our duty as physicians to understand the available treatment options for our patients, and medical cannabis treatments have emerged as an important clinical tool.

Programs 108

Programs Research and Development Education Treatment 108

Cannabis Law Report

AUGUST 21, 2019

In November 2018, the legal status of cannabis was changed to allow specialist clinicians to legally prescribe cannabis-derived medicinal products to patients with an exceptional clinical need, following a high-profile media campaign. The final guideline is expected to be published in November 2019.

Clinical Trials 81

Clinical Trials Nerve Pain Medicine Epilepsy 81

Cannabis Law Report

JULY 6, 2021

Professor Johnson also received national media attention for his appearance in the Home Box Office (HBO) original documentary feature, “Addiction”, which won the prestigious Governors Award, a special Emmy Award, from the Academy of Television Arts and Sciences. ” About Ehave, Inc. Ehave, Inc.

Research and Development 97

Research and Development Wellness and Beauty Clinical Trials Therapy 97

Cannabis Law Report

NOVEMBER 23, 2021

London, UK – 23 November 2021 COMPASS Pathways plc a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has been granted its fifth patent by the US Patent and Trademark Office. PRESS RELEASE. ” About COMPASS Pathways.

Clinical Trials 52

Clinical Trials Therapy Research and Development Media 52

Cannabis Law Report

NOVEMBER 22, 2019

. “As MMJ International Holdings continues to advance to its clinical trials, a specialty pharmaceutical solutions company will be supporting MMJ with the FDA, DEA required development API and specialized liquid encapsulation solutions,” said Elio Mariani, PhD, EVP of Research & Development. 561-627-9455. 917-562-9610.

DEA 51

DEA Clinical Trials THC Research and Development 51

Cannabis Law Report

APRIL 21, 2022

The availability of larger quantities of cGMP-compliant MDMA will facilitate ongoing clinical trials and provide for future therapeutic use following anticipated regulatory approvals. Publication of this process establishes “prior art,” contributing to MAPS’ patient access strategy by making intellectual property public .

Clinical Trials 52

Clinical Trials Research and Development Therapy Media 52

Cannabis Law Report

JUNE 30, 2021

In addition, the company aims to predict what treatments are most effective in addressing these conditions, including psychedelics, which have shown tremendous promise in early clinical trials. Despite the high prevalence of these disorders, few patients are accurately screened and diagnosed. Mental Health Challenges.

Treatment 52

Treatment Clinical Trials Research and Development Data 52

Cannabis Law Report

JULY 9, 2021

Clinical trials involving psychedelic drugs and substances are, however, permitted, provided they comply with both state and federal laws applicable to such trials. For further information: For media inquiries: Contact Jonathan McGuire, Assistant Vice President, Corporate Communications, Horizons ETFs Management (Canada) Inc.,

Data 105

Data Clinical Trials Decriminalization Hemp 105

CannaMD

MARCH 8, 2021

If you’re a Florida medical marijuana patient, chances are you’ve heard of House Bill 1455 – a proposed bill making its rounds through the state legislature as we speak. But, behind the outrage, lies a larger conversation regarding free speech, fair pricing, and the sanctity of the physician-patient relationship.

THC 116

THC Research and Development Treatment Patients 116

Project CBD

FEBRUARY 28, 2023

In December 2021, Leafreport, an online CBD resource owned by Empire Media Network, published the results of analyses of 221 CBD products it sent to third-party laboratories for testing. Available at: www.fda.gov/media/131878/download. 17 Excerpted from HerbalGram , the quarterly publication of the American Botanical Council.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

OCTOBER 22, 2021

SPL026 entered clinical trials at the beginning of 2021 and this designation marks an important step forward towards an accelerated drug approval pathway for bringing the benefits of SPL026 to market for patients suffering with MDD.”. Media Relations Contact. Key partnering stakeholders include the MHRA, the U.K.’s

Therapy 52

Therapy Clinical Trials Research and Development Treatment 52

Cannabis Law Report

JULY 7, 2021

Current TNF-a inhibitors available today, while effective, come with an array of adverse effects and concerns for patients,” said Adam Kaplin, M.D., Media Contact: Will Johnson. inhibitors are the most prescribed drugs by revenue globally, at $40 billion per year. Chief Scientific Officer for MyMD. Investor Contact: Robert Schatz.

Pharmaceutical 81

Pharmaceutical Data Clinical Trials Research and Development 81

The Cannigma

JULY 1, 2022

These claims influence things like how consumers purchase cannabis or how doctors consult with medical cannabis patients. What if most of it is not based on the level of scientific certainty that cannabis marketing teams and media outlets would have us believe? The cannabis research problem.

Research and Development 108

Research and Development Data THC Clinical Trials 108

Cannabis Law Report

NOVEMBER 16, 2019

Current barriers to patient access to medicinal cannabis in Australia. On 14 November 2019, the Senate referred an inquiry into the current barriers to patient access to medicinal cannabis in Australia to the Senate Community Affairs References Committee for inquiry and report by 12 February 2020. Media Releases. Track Inquiry.

Clinical Trials 58

Clinical Trials Access Medicine Patients 58

Cannabis Law Report

OCTOBER 15, 2021

DNA variations or polymorphisms) in patients with African ancestry. The KGA is a proprietary computational platform built in-house at Goldfinch Bio to identify genetic and environmental causes of kidney diseases in patient subsets and the associated biological targets for therapeutic intervention. Poster Number: INFO37.

Clinical Trials 40

Clinical Trials Research and Development Data Patients 40

Cannabis Law Report

JANUARY 13, 2020

We are proud of the positive impact this medicine has already had on thousands of patients and believe that this past year provides a compelling foundation for continued success in 2020,” said Justin Gover, GW’s Chief Executive Officer. Execute NHIE clinical program utilizing an intravenous formulation of cannabidiol. media enquiries.

Pharmaceutical 51

Pharmaceutical Clinical Trials Research and Development Programs 51

Cannabis Law Report

DECEMBER 26, 2021

. “With the filing of our provisional patent application, Entheon is building an IP foundation to better facilitate safe and precise use of psychedelics to deliver improved patient outcomes.” EBRX-101 on Track to Submit Regulatory Package for Human DMT Clinical Trial. ” In Vivo Toxicity Assays Completed.

Research and Development 52

Research and Development Clinical Trials Treatment Packaging 52

Cannabis Law Report

SEPTEMBER 24, 2019

T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

DECEMBER 9, 2021

. “The FDA is supportive of our plans to develop regulated devices that would allow the use of novel analyses of multimodal data to capture, model, and map outputs that, if cleared, could be useful to clinicians and patients in the delivery of psychedelic and other perception-altering substances.” Media Contact: media@mindmed.co.

Research and Development 52

Research and Development Clinical Trials Therapy Medicine 52

Alchimia

JANUARY 25, 2022

At the beginning of this new year of 2022, a news story about how cannabis can help fight COVID-19 was picked up by many non-cannabis media. While this research is certainly worth celebrating, the reality behind the message can be easily misunderstood in this age of social media. THC is also no stranger to the fight.

Research and Development 98

Research and Development Terpenes CBD Treatment 98

Cannabis Law Report

SEPTEMBER 20, 2021

Delic expects to open 15 additional clinics across the country over the coming 18 months, further expanding access to millions who can benefit from psychedelic treatment for a variety of mental health conditions. Adding KWC will ensure our existing patients and many more in the future will receive the best medical treatment and care.

Treatment 52

Treatment Media Research and Development Patients 52

Cannabis Info

OCTOBER 11, 2019

Now, clinical studies are about to get underway at an Australia university, to track changes in actual dementia patients to see if cannabis can help. In the Australian clinical study, cannabinoids will be extracted and delivered in a mouth spray, making it easier to be administered to the elderly. Cannabis research in the U.S.

Treatment 45

Treatment Clinical Trials Cannabinoids Cannabis 45

Cannabis Law Report

DECEMBER 9, 2021

MAPS is sponsoring the most advanced psychedelic therapy research in the world: Phase 3 clinical trials of MDMA-assisted therapy for PTSD. Media Contact nuelife@derris.com. “We are proud to support the profound research of these organizations,” continued Mr. Cappello. ” About Nue Life.

Research and Development 52

Research and Development Therapy Clinical Trials Treatment 52

Cannabis Law Report

APRIL 8, 2022

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. Media coverage of the paper led to a new stigma and political pressure ended the Spain MDMA study. Rick Doblin, Ph.D.,

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

MMJ Recs

JULY 3, 2024

From the pressures of work and personal relationships to the constant bombardment of information on social media and the news, many individuals find themselves struggling to cope with these challenges. For more information, read our post “ Understanding the Endocannabinoid System: A Guide for Medical Marijuana Patients ”.

CBD 52

CBD Research and Development Clinical Trials THC 52

Cannabis Law Report

JANUARY 24, 2022

Accomplished leader to oversee Goldfinch Bio’s clinical function to advance precision medicines for people living with kidney disease. Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887. CAMBRIDGE, Mass.–(BUSINESS

Clinical Trials 40

Clinical Trials Research and Development Data Medicine 40

Cannabis Law Report

OCTOBER 17, 2019

The introduction of these protocols will take the form of clinical trials and research that will include the usage of specific strains of cannabis that aid in chronic pain and cancer treatments. Media Relations. Tree of Knowledge will be introducing chronic pain management protocols and research into the Caribbean market.

Clinical Trials 40

Clinical Trials Research and Development Chronic Pain CBD 40

The Blunt Truth

AUGUST 13, 2019

The FDA is also meeting with other federal agencies and state counterparts, trade organizations, and patient groups in a quest for data. On Friday, July 26, 2019, Curaleaf responded, noting that it has taken steps to review all inaccurate statements about CBD products from their websites and social media platforms.

CBD 80

CBD Food Seed-To-Sale Wellness and Beauty 80

Cannabis Law Report

SEPTEMBER 1, 2019

The Victorian and New South Wales Governments had both begun clinical trials of cannabis products for children with severe epilepsy and for palliative care, respectively. Minister for Industry and Skills David Pisoni published a media release to mark the occasion, entitled South Australia welcomes cannabis industry leaders.

Clinical Trials 53

Clinical Trials Research and Development Medicine Cultivation 53

Cannabis Law Report

JULY 15, 2022

Sunshine Coast based Tikun Oceana, formerly known as Medifarm , is now under the control of administrators from Cor Cordis.The company was founded …… Predictably Murdoch media has this behind a paywall if you want to pay to learn more. Media event date: 27 August 2019. Media type: Transcript.

Medicine 52

Medicine Patients Media Supply Chain 52

MMJ Recs

DECEMBER 22, 2023

Public discourse became more nuanced, with patients and advocacy groups championing the cause of medical marijuana as a legitimate and effective treatment option. Another influential factor is the growing emphasis on individual autonomy and patient choice in healthcare.

Marijuana 52

Marijuana Chronic Pain Advocacy Research and Development 52

Cannabis Law Report

OCTOBER 29, 2021

The highlights for the quarter are: As previously disclosed, on September 7, 2021, the Company announced the completion of its Phase 1 clinical trial on IGC’s tetrahydrocannabinol (“THC”) based investigational new drug, IGC-AD1, intended to alleviate certain symptoms of individuals who have Alzheimer’s disease.

Clinical Trials 40

Clinical Trials Research and Development Data Business 40

Cannabis Law Report

DECEMBER 6, 2021

“We look forward to Jeff’s significant contributions heading into another year of continued growth and progress for Goldfinch Bio, including a planned interim data readout from TRACTION-2, the ongoing Phase 2 clinical trial of our lead precision kidney medicine candidate, in mid-2022.”. Media: Liz Melone. 212-362-1200.

Research and Development 40

Research and Development Supply Chain Clinical Trials Medicine 40